Laurence DELHAES

Education/Training • 2012: Specialization in Tropical infection diseases, University of Angers • 2007: HDR (ability to supervise PhD; Field: Microbiology, Mycology, and Parasitology) University of Lille II • 2000: PhD (Field: Microbiology and immunology) University of Lille II • 1995: MD (Field: Infectious Diseases) University of Poitiers Positions and Honors - Current position: Professor (PU-PH) Head of Parasitology-Mycology Department at Hospital of Bordeaux University, In charge of the research axis: “Lung inflammatory chronic diseases and mycobiome”, team 2 INSERM U1045, «ACRONIM» Federation, University of Bordeaux - Other Experience and Professional Memberships • Since 2018: Deputy Scientific co-Director of the Genome-Transcriptome Platform of Bordeaux University • Since 2016: In charge of the research field: “Lung, inflammatory chronic and pro- eukaryotic microbiota”, Team 2, Pr P Berger, INSERM U1045, ACRONIM Federation at Bordeaux University • 2006-2015: in charge of the research group: “Lung, inflammatory chronic and pro- eukaryotic microbiota”, BDPEE team, Dr E. Viscogliosi, CIIL, Institute Pasteur of Lille) • 2012-2016: Member of the scientific comity of InVS (Institut National de Veille Sanitaire) • 2011-2015: In charge of the working group « Ethics and Research » Ethics department (EEHU) of Lille Contributions to Science For several years, I have been working on Aspergillus and Scedosporium models, as well as on clinical trials focused on fungal risks in chronic pulmonary diseases such as asthma and cystic fibrosis (CF). My major objective was to establish reliable prevalence of fungal colonization or infection, and clinical relevance of moulds isolated from respiratory tract of patients with chronic respiratory diseases. To be able to compare data from one centre or country to another, with my research group we first aimed at developing a consensual standardized protocol for current mycological analysis, through both a national and an international study she coordinated. More recently I acquired expertise on mycobiome analysis and high-throughput genomics, and joined in 2016 Inserm U-1045 (P Berger’s Team) to develop molecular and cellular analysis of mycobiome impact on cell remodelling in chronic pulmonary diseases. Presently, I'm setting up the deployment of clinical trials combined with the mycobiome-microbiome analysis of lung samples of asthmatic or CF patients, and with in-vitro experiments based on an ALI or bronchial epithelial, plus microbial coinfections of in-vitro cultures of cells. I was chair of the French Society of Parasitology (2015-2019), and has authored more than 100 peer reviewed publications, and 6 reviews/chapters, (Index h = 38, i10 = 72 according to Google Scholar analysis), and managed fundings (detailed below).